NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for its intranasal drug NEO100 in patients with recurrent IDH1-mutant high-grade ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA